Recent News

ASCO 2021: KarMMa Update of BCMA-Directed CAR T-Cell Therapy for Refractory Myeloma

EHA2021: Iberdomide-Based Regimens for Relapsed or Refractory Multiple Myeloma

EHA2021: MAIA Trial Update on Daratumumab-Based Therapy for Newly Diagnosed Myeloma

ASCO 2021: Interim Analysis of CASSIOPEIA Trial of Daratumumab Maintenance in Myeloma

ASCO 2021: Ixazomib Maintenance After HCT in High-Risk Multiple Myeloma

Final Evidence Report From ICER on Three Therapies Targeting BCMA for Myeloma

BCMA CAR T-Cell Therapy Granted Priority Review for Multiple Myeloma

Ixazomib, Lenalidomide, and Dexamethasone in Myeloma: Routine Clinical Practice Versus Clinical Trials

Selinexor-Based Triplet in Myeloma: Impact of Age and Frailty in BOSTON Trial

Combination of Novel Antimyeloma Prototype and Cyclopamine Under Study

Does the First COVID-19 Vaccine Dose Offer Protection for Patients With Multiple Myeloma?

Peritransplant Orthostatic Hypotension and Multiple Myeloma

Frailty-Guided Treatment Strategy for Newly Diagnosed Patients With Myeloma

Risk Factors for Bloodstream Infections and Early Mortality in Multiple Myeloma

Whole-Genome Sequencing May Offer Insights to Multiple Myeloma Precursor Conditions

AACR 2021: Synergistic Selinexor-Based Combinations and Companion Biomarkers in Myeloma

Newly Diagnosed Myeloma: Novel Scenario for Carfilzomib-Linked Thrombotic Microangiopathy

AACR 2021: Role of ROBO1 Receptor in Growth of Multiple Myeloma

Weekly Carfilzomib-Based Regimen in Resistant Myeloma: Phase II Trial

Novel Oral PIM Kinase Inhibitor Under Study in Resistant Multiple Myeloma

Newly Diagnosed Myeloma: Novel Scenario for Carfilzomib-Linked Thrombotic Microangiopathy

AACR 2021: Is Novel IKZF1/3 Degrader Active Against Multiple Myeloma?

Isatuximab/Pomalidomide/Dexamethasone in Myeloma: Is Prescreening Patients for Biomarkers Warranted?

ICER Releases Evidence Report on BCMA Therapies for Multiple Myeloma

Expert European Panel Provides Clinical Practice Guidelines for Multiple Myeloma

Use of Generic Pomalidomide in India for Resistant Multiple Myeloma

Daratumumab-Based Therapy for Myeloma: Patient-Reported Outcomes From CASTOR Trial

FDA Approves Isatuximab-irfc Combination Therapy for Multiple Myeloma

FDA Approves First Cell-Based Gene Therapy for Multiple Myeloma

Early Access Treatment Protocol of Daratumumab in European and Russian Patients With Resistant Myeloma

Combination Regimens for Transplant-Ineligible Myeloma: From the Canadian Myeloma Research Group

Avelumab Plus Hypofractionated Radiotherapy for Resistant Multiple Myeloma

Cardiac Repolarization After Daratumumab Monotherapy for Smoldering Multiple Myeloma

Idecabtagene Vicleucel Under Study in Relapsed and Refractory Multiple Myeloma

Isolated Radiotherapy for Myeloma Lesions of the Cervical Spine: Case Report

Collaborative Initiative Offers Recommendations to Improve Diversity in Myeloma Trials

Long-Term Outcomes With Standard-of-Care Strategy in Multiple Myeloma

Melphalan Flufenamide Receives Accelerated Approval for Resistant Multiple Myeloma

Taking on Myeloma and Prostate Cancer: A Man Named Steele

TCT 2021: Is Idecabtagene Vicleucel Safe for Elderly Patients With Resistant Myeloma?

Does a Patient’s Race Affect Access to IV Bisphosphonates in Multiple Myeloma?

Ixazomib Plus Standard Therapy for Myeloma: Outcomes in Routine Clinical Practice

Selinexor Triplet Under Study in Resistant Multiple Myeloma

Continued Trials for Iberdomide in Combination Therapy for Resistant Myeloma

Seeking the Right Dose of Immunoconjugate Combination in Resistant Myeloma

Corneal Changes With Antibody-Drug Conjugate in Myeloma: Mechanism Remains Unknown

Ixazomib Plus Standard Therapy in Transplant-Ineligible Patients With Myeloma

Cyclophosphamide Plus Weekly Carfilzomib and Dexamethasone in Resistant Myeloma

Carfilzomib-Based Therapy for High-Risk Smoldering Multiple Myeloma

Is Hypercalcemia Linked to Poor Survival in Newly Diagnosed Multiple Myeloma?

Investigational Immunotherapy Focus of Phase I Trial in Resistant Myeloma

ASH 2020: Intravenous and Subcutaneous Teclistamab for Resistant Multiple Myeloma

Selinexor Approved by FDA for Refractory or Relapsed Multiple Myeloma